Telix Pharmaceuticals Limited (TLX) financial statements
Telix Pharmaceuticals Limited reported revenue of $804M in fiscal 2025, up 55.4% a year over 2 years.
Net income was -$7M and the operating margin 3.7%, against 3.3% in 2023.
Free cash flow was -$61M.
The diluted share count rose 4% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Telix Pharmaceuticals Limited's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $333M | $517M | $804M |
| Cost of revenue | $123M | $180M | $377M |
| Gross profit | $210M | $336M | $426M |
| Research and development | $85M | $128M | $171M |
| Selling, general and admin | $50M | $85M | $96M |
| Operating income | $11M | $55M | $30M |
| Interest expense | $97,000 | $64,000 | $181,000 |
| Pre-tax income | $3M | $38M | -$5M |
| Income tax | -$2M | $4M | $2M |
| Net income | $4M | $34M | -$7M |
| EPS (diluted) | $0.01 | $0.10 | -$0.02 |
| Diluted shares | 324M | 345M | 338M |
| Gross margin | 62.9% | 65.1% | 53.1% |
| Operating margin | 3.3% | 10.7% | 3.7% |
| Net margin | 1.3% | 6.5% | -0.9% |
Balance sheet
Fiscal years, from Telix Pharmaceuticals Limited's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cash and short-term investments | $84M | $440M | $142M |
| Receivables | $44M | $87M | $129M |
| Inventory | $13M | $24M | $37M |
| Total current assets | $159M | $570M | $330M |
| Property, plant and equipment | $16M | $28M | $59M |
| Goodwill | — | $67M | $199M |
| Total assets | $277M | $940M | $1.2B |
| Total current liabilities | $111M | $205M | $232M |
| Long-term debt | $6M | $342M | $392M |
| Total liabilities | $175M | $587M | $749M |
| Shareholders' equity | $103M | $353M | $415M |
| Net debt | -$78M | -$86M | $263M |
Cash flow
Fiscal years, from Telix Pharmaceuticals Limited's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | $14M | $27M | -$17M |
| Capital spending | $7M | $22M | $44M |
| Free cash flow | $7M | $5M | -$61M |
| Stock-based compensation | $6M | $13M | $19M |
| Net borrowing | $4M | $427M | -$290,000 |
| Free cash flow margin | 2.2% | 1.0% | -7.6% |
Questions
What was Telix Pharmaceuticals Limited's revenue in 2025?
$804M in fiscal 2025, from its 10-K filing.
How much free cash flow does Telix Pharmaceuticals Limited generate?
-$61M in fiscal 2025 (operating cash flow minus capital spending).
From Telix Pharmaceuticals Limited's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.